Jan Lang

Cooley advised General Catalyst Partners, a venture capital firm providing early-stage and growth equity investments, as the lead investor in Helsing’s 209 million euro Series B financing.

Cooley advised Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, on its strategic collaboration with Moderna.

Cooley advised Condor, a German leisure airline, in its victory against the approval of Lufthansa’s 2020 state bailout.

A Cooley team advised Horizon Therapeutics, a specialty biopharmaceutical company, on its agreement to be acquired by Amgen. The approximately $28 billion merger would represent the third-largest all-cash transaction in the pharmaceutical sector in history and the biggest healthcare deal of 2022.

Cooley advised Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, on its license, development and commercialization agreement with Bristol Myers Squibb for its TCR bispecific candidate, IMA401. Lawyers Ken Krisko, Carly Robinson, Brian Stalter and Stephanie Palmer led the Cooley team advising Immatics.